Cooley’s 2020 Life Sciences M&A Year in Review
Cooley M&A
JANUARY 22, 2021
COVID-19 drove unprecedented levels of collaboration among biopharmaceutical companies seeking to develop a vaccine, leading to an accelerated research and development process that allowed not just one—but two—vaccines to be approved by the FDA in record-breaking time. An Evolving Transactional Landscape.
40 
Let's personalize your content